OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Demetri Explains the Side Effects of Regorafenib

June 20th 2012

Dr. George Demetri, from Dana-Farber Cancer Institute, Explains the Side Effects Associated With Regorafenib.

Dr. Gandara on TS Expression in ALK-Positive NSCLC

June 19th 2012

Dr. David Gandara, from UC Davis Cancer Center, on Thymidylate Synthase Expression in ALK-Positive Non-small Cell Lung Cancer

Dr. Arnold on Second-Line Avastin Continuation for mCRC

June 19th 2012

Dr. Dirk Arnold, from the University Cancer Center Hamburg, Germany, on Second-Line Bevacizumab Continuation Therapy for Metastatic Colorectal Cancer

Dr. Ryan Discusses Sequencing Prostate Cancer Therapies

June 18th 2012

Dr. Charles Ryan, from UCSF Helen Diller Family Comprehensive Cancer Center, Discusses Sequencing Castration-Resistant Prostate Cancer Therapies.

Dr. Kris Discusses ASCO 2012 Lung Cancer Information

June 18th 2012

Dr. Mark Kris, from Memorial Sloan-Kettering Cancer Center, Discusses Lung Cancer Information Presented at the 2012 ASCO Annual Meeting.

Dr. Escudier on Patients Preferring Pazopanib for mRCC

June 15th 2012

Dr. Bernard Escudier, from the Institut Gustave Roussy, on Patients Preferring Pazopanib for Metastatic Renal Cell Carcinoma.

Dr. Jorge Cortes Discusses the Ponatinib PACE Trial

June 14th 2012

Dr. Jorge Cortes, from the MD Anderson Cancer Center, Discusses the Ponatinib Ph+All and CML Evaluation (PACE) Trial

Dr. Concepcion on Bladder Cancer Treatment and Costs

June 14th 2012

Dr. Raoul Concepcion, from the Urology Associates, PC, Nashville, TN, on Bladder Cancer Treatment and Costs.

Dr. Cohen Discusses the Cabozantinib EXAM Trial

June 13th 2012

Dr. Ezra Cohen, from the University of Chicago, Discusses the Cabozantinib (XL184) EXAM Trial

Dr. Adjei on the Need for Targeted Therapy Education

June 12th 2012

Dr. Alex Adjei, from Roswell Park Cancer Institute, on the Need for Targeted Therapy Education

Dr. Ryan on the COU-AA-302 Interim Analysis Results

June 11th 2012

Dr. Charles Ryan, from the UCSF Diller Family Comprehensive Cancer Center, on the COU-AA-302 Abiraterone Acetate Interim Analysis Results.

Dr. Baselga on Combining Pertuzumab with Trastuzumab

June 8th 2012

Dr. JosÃ© Baselga, from Massachusetts General Hospital, on combining pertuzumab with trastuzumab

Dr. Shore Discusses the Enzalutamide AFFIRM Trial

June 8th 2012

Dr. Neal Shore, from the Atlantic Urology Clinics, Discusses the Enzalutamide (MDV3100) AFFIRM Trial

Dr. Taplin on Neoadjuvant Abiraterone and Leuprolide

June 8th 2012

Dr. Mary-Ellen Taplin, from Dana-Farber Cancer Institute, on Neoadjuvant Abiraterone Acetate and Leuprolide Acetate

Dr. Brahmer on the PD-1 Immunotherapy BMS-936558

June 7th 2012

Dr. Julie Brahmer, from the Sidney Kimmel Comprehensive Cancer Center, on the PD-1 Immunotherapy BMS-93655 Clinical Trial

Dr. Larsen Discusses Outcomes for AYA ALL Patients

June 7th 2012

Dr. Eric Larsen, from the Maine Children's Cancer Program, Discusses Outcomes for AYA Patients With Acute Lymphoblastic Leukemia

Dr. Concepcion Discusses Prostate Cancer Therapies

May 31st 2012

Dr. Raoul Concepcion, from Urology Associates, PC, Nashville, TN, Discusses New Prostate Cancer Therapies.

Dr. Markman on Long-Term Chemotherapy Side Effects

May 29th 2012

Dr. Maurie Markman, from Cancer Treatment Centers of America, on Awareness of Long-Term Chemotherapy Side Effects

Dr. Sieber on Managing Bone Health After ADT

May 25th 2012

Dr. Paul Sieber, from the Urological Association of Lancaster, on Managing Bone Health After the Introduction of ADT.

Krista Rubin on Understanding Ipilimumab's Toxicities

May 24th 2012

Krista Rubin, from Massachusetts General Hospital Cancer Center, on Understanding Ipilimumab's Toxicities.